Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Trulicity Summary of Product Characteristics (SmPC)

How should other medications be administered with Trulicity® (dulaglutide)?

Consider reducing insulin/insulin secretagogue dose when initiating Trulicity (dulaglutide). Dulaglutide may reduce absorption of orally co-administered drugs.

Detailed Information

Potential for Dulaglutide to Influence the Pharmacokinetics of Other Drugs

Dulaglutide slows gastric emptying and, as a result, may reduce the extent and rate of absorption of orally coadministered medications.1

In clinical pharmacology studies, treatment with dulaglutide did not affect, to any clinically relevant degree, the absorption of coadministered oral medications that included

  • lisinopril

  • warfarin

  • metoprolol

  • digoxin

  • norelgestromin

  • ethinylestradiol

  • atorvastatin

  • metformin

  • paracetamol, and

  • sitagliptin.1

No dose adjustment is recommended for any of these evaluated coadministered medications.1

Concomitant Use With an Insulin Secretagogue or With Insulin

To reduce the risk of hypoglycemia when initiating dulaglutide treatment, consider reducing the dosage of concomitantly administered

  • insulin secretagogues, such as sulfonylureas, or

  • insulin.1

References

1. Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Date of Last Review: July 13, 2020


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request